pH-responsive virus-drug conjugates for targeted PD-L1 silencing and enhanced cancer immunotherapy
Summary
No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.
Summarise with VIRAT Free to try with your Science Catalogs account.Abstract
Clinical efficacy of virotherapy is often limited by poor transduction and off-target effects. To overcome these hurdles, we engineered a multi-stage, pH-responsive virus-drug conjugate (VDC) for targeted, cancer immunotherapy. Our VDC comprises a recombinant adeno-associated virus serotype 2 (AAV2) encoding a programmed death-ligand 1 (PD-L1) short hairpin RNA (shRNA), which is chemically conjugated to the transduction-enhancing doxorubicin (Dox) with minimally cytotoxic dosage. This AAV2-Dox is shielded by a polyethylene glycol (PEG) layer attached via a pH-sensitive benzoic-imine linker, designed to be stable at physiological pH but cleavable within the acidic tumor microenvironment. AAV2-Dox produced an equivalent enhancement of transgene expression at a much lower concentration (0.005 µg mL − 1 ) than Dox alone (0.02 µg mL − 1 ). The pH-sensitive PEG shield successfully renders the VDC inert at pH 7.4 while restoring full transduction and therapeutic efficacy upon acid-triggered unshielding. Mice treatment with the PEGylated AAV2-Dox leads to efficient PD-L1 knockdown, which enhanced T-cell infiltration and polarization toward M1 macrophages. This study establishes a smart VDC platform that integrates a transduction enhancer with a gene therapy payload under the control of an acidic tumor microenvironment-activated stealth shield. This strategy provides a new paradigm for developing safer and more potent nanomedicines for combinatorial cancer immunotherapy.
Fields of Study & Subjects
Virus-based gene therapy research
Nanoparticle-Based Drug Delivery
RNA Interference and Gene Delivery
Publication details
- Journal / source
- Journal of Nanobiotechnology
- Volume
- 24
- Issue
- 1
- Publication date
- 30 March 2026
- Language
- EN